N-(叔丁氧羰基L)-S-甲基-L-半胱氨酸 | 16947-80-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 半胱氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(叔丁氧羰基L)-S-甲基-L-半胱氨酸
• 中文别名: N-(叔丁氧羰基l)-S-甲基-L-半胱氨酸；N-Boc-S-甲基-L-半胱氨酸
• 英文名称: N-(tert-butoxycarbonyl)-S-methyl-L-cysteine
• 英文别名: (R)-2-(N-tert-butoxycarbonylamino)-3-methylthiopropanoic acid；(2R)-2-(tert-butoxycarbonylamino)-3-methylsulfanylpropanoic acid；N-(tert-butoxycarbonyl)-S-methylcysteine；N-tert-butoxycarbonyl-S-methylcysteine；N-Boc-S-methyl-L-cysteine；Boc-L-methylthioalanine；(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-methylsulfanylpropanoic acid
• CAS: 16947-80-1
• 化学式: C₉H₁₇NO₄S
• 分子量: 235.304
• InChiKey: WFDQTEFRLDDJAM-LURJTMIESA-N

物化性质

• 熔点：
  71-73 °C
• 沸点：
  388.7±37.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  常温常压下稳定。 避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2930909090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Boc-Cys(Me)-OH
Product Name:
Synonyms: (2R)-2-[(TERT-BUTOXYCARBONYL)AMINO]-3-(METHYLSULFANYL)PROPANOIC ACID

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Boc-Cys(Me)-OH
Ingredient name:
CAS number: 16947-80-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H17NO4S
Molecular weight: 235.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(叔丁氧羰基L)-S-甲基-L-半胱氨酸 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.5h， 生成 tert-butyl [1-hydroxy-3-(methylsulfanyl)propan-2-yl]carbamate
  参考文献：
  名称：

  克服诱变性和离子通道活性：选择性脾酪氨酸激酶抑制剂的优化

  摘要：

  描述了开发一系列具有良好药物样特性的高促动素选择性脾酪氨酸激酶（Syk）抑制剂。通过X射线晶体学分析，以及对选定化学空间内核心的系统调查（以配体结合效率为重点），发现了早期的铅。通过调节包括log D，PSA和p K a在内的物理化学性质来指导初始化学型中固有的hERG离子通道活性的减弱。PSA被证明对预期的化合物设计最有效。使用TA97a沙门氏菌的Ames试验进一步分析了先进化合物的细菌致突变性菌株，随后的研究表明，这种诱变性在整个系列中普遍存在。插入的鉴定是核心支架诱变启用修饰的可能机制。将DNA结合测定作为DNA的预筛选和模型，可以解决诱变风险，为分子提供了有利的效价，选择性，药代动力学和脱靶特性。

  DOI：

  10.1021/jm5018169
• 作为产物：
  描述：

  N-[(tert-butoxy)carbonyl]-L-cysteine methyl ester 在 水 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-(叔丁氧羰基L)-S-甲基-L-半胱氨酸
  参考文献：
  名称：

  Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors

  摘要：

  MAPK通路异常在癌症的发生和发展中起着至关重要的作用。作为该通路的关键上游介质，RAS GTP酶在30%的人类癌症中发生突变。聚异戊二烯基半胱氨酸酰胺抑制剂（PCAIs）被设计为针对RAS驱动的癌症的潜在靶向治疗。当前研究报告了PCAIs的优化以及确定它们在KRAS突变癌细胞中的作用机制。它们的ClogP值范围从3.01到6.35，抑制了KRAS突变的MDA-MB-231、A549、MIA PaCa-2和NCI-H1299细胞在2D和3D培养中的存活率，相应的EC50值分别为2.2至6.8、2.2至7.6、2.3至6.5和5.0至14微米。当A549细胞用PCAIs NSL-YHJ-2-27处理48小时时，总体或磷酸化的B-和C-Raf蛋白水平没有显著差异。然而，在5微米时，相对于对照组，它分别刺激了MEK1/2、ERK1/2和p90RSK的磷酸化分别增加了84%、59%和160%。一种非法尼醇化的类似物NSL-YHJ-2-62没有产生类似效果。这些数据揭示了PCAIs对RAS-MAPK信号通路的影响很可能是其抗癌作用的原因，可能是通过p90RSK的凋亡诱导亚型。因此，PCAIs可能有潜力满足患有异常高活性G蛋白信号的患者的治疗需求。

  DOI：

  10.3390/cancers13225757
• 作为试剂：
  描述：

  N-(叔丁氧羰基L)-S-甲基-L-半胱氨酸 、 (R)-N-tert-butyl-3-<(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl>-1,3-thiazolidine-4-carboxamide 在 N-(叔丁氧羰基L)-S-甲基-L-半胱氨酸 作用下， 生成 (R)-N-tert-butyl-3-[(2S,3S)-3-[(S)-2-(tert-butoxycarbonyl)amino-3-methylthiopropionyl]amino-2-hydroxy-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide
  参考文献：
  名称：

  Chemical and Pharmaceutical Bulletin 1992, 40, 2251-2253

  摘要：

  DOI：

文献信息

• [EN] NITROGEN-CONTAINING HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013018929A1

  公开（公告）日：2013-02-07

  The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种新型的化合物，作为一种ERR-α调节剂具有优越的活性，并可作为预防或治疗与ERR-α相关疾病的药物。本发明涉及一种由公式(1)表示的化合物，其中每个符号如说明书中所定义，或其盐。
• [EN] 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE LA RATE (SYK) CONTENANT UN 2-PYRIDYL CARBOXAMIDE
  申请人：MERCK SHARP & DOHME

  公开号：WO2013052394A1

  公开（公告）日：2013-04-11

  The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了一些含有2-吡啶甲酰胺的化合物，其化学式为(I)或药用可接受的盐，其中A和B按本发明定义。本发明还提供了包含这些化合物的药物组合物，以及使用这些化合物来治疗由脾酪氨酸激酶（Syk）介导的疾病或状况的方法。
• NITROXOLINE PRODRUG AND USE THEREOF
  申请人：Jiangsu Yahong Meditech Co., Ltd.

  公开号：US20210363165A1

  公开（公告）日：2021-11-25

  Provided are a nitroxoline prodrug and a use thereof. Specifically, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a composition containing the compound, and a use thereof in the preparation of anti-infective and antitumor drugs, and definitions of groups in formula (I) are as stated in the specification. The compound represented by formula (I) has better pharmacokinetic parameters such as solubility, blood medicine concentration, or half-life period than nitroxoline. The compound represented by formula (I) can reduce the frequency of drug administration, and has potential for application in other fields other than the field of urinary tracts.

  提供了一种硝基喹啉前药及其用途。具体提供了一种由式（I）表示的化合物或其药学上可接受的盐，其制备方法，含有该化合物的组合物，以及在制备抗感染和抗肿瘤药物中的用途，式（I）中的基团定义如规范中所述。由式（I）表示的化合物具有比硝基喹啉更好的药代动力学参数，如溶解度、血药浓度或半衰期。由式（I）表示的化合物可以减少药物给药频率，并且在泌尿道领域之外的其他领域具有应用潜力。
• Polypeptides. Part V. The use of t-butyl 2,4,5-trichlorophenyl carbonate in the synthesis of N-t-butoxycarbonyl amino-acids and their 2,4,5-trichlorophenyl esters
  作者：Wallace Broadbent、J. S. Morley、B. E. Stone

  DOI：10.1039/j39670002632

  日期：——

  t-Butyl 2,4,5-trichlorophenyl carbonate, conveniently prepared from phosgene in two stages, reacts cleanly with amino-acids in the presence of bases to give N-t-butoxycarbonyl amino-acids (and 2,4,5-trichlorophenol) in excellent yield. By co-extraction of the N-t-butoxycarbonyl amino-acid and 2,4,5-trichlorophenol from the acidified reaction mixture, followed by treatment of the extracts with NN′-

  碳酸叔丁酯2,4,5-三氯苯甲酸，方便地从光气中分两步制备，在碱的存在下与氨基酸干净地反应，得到N-叔丁氧羰基氨基酸（和2,4,5-三氯苯酚）的良率。由的共萃取Ñ -t丁氧羰基氨基酸及从所述酸化反应混合物2,4,5-三氯苯酚，接着处理所述提取物的具有NN '-dicyclohexylcarbodi酰亚胺，相应的高收率Ñ -t得到-丁氧基羰基氨基酸2,4,5-三氯苯基酯。这些活性酯大部分是稳定的结晶固体，可以方便地用于肽合成中。
• [EN] DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC)<br/>[FR] COMPOSÉS DITERPÉNOÏDES AGISSANT SUR LA PROTÉINE KINASE C (PKC)
  申请人：K GEN INC

  公开号：WO2021062030A1

  公开（公告）日：2021-04-01

  This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

  本公开涉及蛋白激酶C（PKC）调节化合物，使用这些化合物治疗癌症患者的方法，以及与第二治疗剂联合治疗的方法。